Targeted therapies that block specific signaling pathways critical for cancer cell survival have improved outcomes for certain cancers, with notable examples such as inhibitors of epidermal growth factor receptor, HER2, estrogen receptor, and vascular endothelial growth factor receptor, as well as multikinase inhibitors, 3. This evidence concerns the gene EGFR and cancer.